Henry Schein (HSIC) Aktienübersicht
Henry Schein, Inc. bietet Gesundheitsprodukte und -dienstleistungen für niedergelassene Zahnärzte und Mediziner weltweit an. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 4/6 |
| Künftiges Wachstum | 1/6 |
| Vergangene Leistung | 1/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 0/6 |
HSIC Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Henry Schein, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$86.43 |
| 52-Wochen-Hoch | US$89.29 |
| 52-Wochen-Tief | US$61.95 |
| Beta | 0.81 |
| 1 Monat Veränderung | 11.59% |
| 3 Monate Veränderung | 17.03% |
| 1 Jahr Veränderung | 17.67% |
| 3 Jahre Veränderung | 7.98% |
| 5 Jahre Veränderung | 12.22% |
| Veränderung seit IPO | 1,419.65% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jun 25
HSIC: Healthy Dental Trends And Cost Controls Are Expected To Support Balanced Outlook
Analysts have nudged their price target for Henry Schein higher, with fair value moving from about $87.21 to $88.07, as they point to healthier dental markets, recent margin improvement and a more constructive view on the stock following the latest research updates. Analyst Commentary Recent research around Henry Schein highlights a mix of optimism on the core dental business and cost structure, alongside some lingering caution on areas like medical growth and valuation risk.Seeking Alpha • Jun 22
Henry Schein: Smile Because The Upside Isn't Over
Summary Henry Schein remains a dominant global provider in dental and medical practitioner supplies, with strong market shares and ongoing revenue growth. HSIC's Q1 2026 revenue grew 6.3% year-over-year, driven by robust global dental merchandise and equipment demand, particularly in aging and expanding populations. Profitability metrics are mixed, but adjusted net income and EBITDA are rising; management guides for 3–5% revenue growth and mid-single-digit EBITDA growth in 2026. Valuation remains attractive relative to peers, supporting a continued 'buy' rating based on industry leadership, growth catalysts, and reasonable multiples. Read the full article on Seeking AlphaAnalyseartikel • Jun 16
Henry Schein (HSIC) Stock Could Be 7% Undervalued After BTIG Upgrade
BTIG’s recent upgrade of Henry Schein (HSIC), citing solid dental segment trends and cost-saving efforts that support profitability, has drawn fresh attention to the stock and how investors interpret evolving industry pressures. See our latest analysis for Henry Schein. The recent BTIG upgrade comes after a period where Henry Schein’s 1 month share price return of 11.51% and 1 year total shareholder return of 14.60% suggest improving momentum following more modest multi year gains. If this...Narrativ-Update • Jun 11
HSIC: Dental Demand And Cost Controls Are Expected To Support Balanced Outlook
Analysts have raised their average price target on Henry Schein to $100. They cite recent commentary around generally healthy dental markets, margin gains in Q1 driven by cost reductions, and a view that the stock has found technical support.Recent updates
Narrativ-Update • Jun 25
HSIC: Healthy Dental Trends And Cost Controls Are Expected To Support Balanced Outlook
Analysts have nudged their price target for Henry Schein higher, with fair value moving from about $87.21 to $88.07, as they point to healthier dental markets, recent margin improvement and a more constructive view on the stock following the latest research updates. Analyst Commentary Recent research around Henry Schein highlights a mix of optimism on the core dental business and cost structure, alongside some lingering caution on areas like medical growth and valuation risk.Seeking Alpha • Jun 22
Henry Schein: Smile Because The Upside Isn't Over
Summary Henry Schein remains a dominant global provider in dental and medical practitioner supplies, with strong market shares and ongoing revenue growth. HSIC's Q1 2026 revenue grew 6.3% year-over-year, driven by robust global dental merchandise and equipment demand, particularly in aging and expanding populations. Profitability metrics are mixed, but adjusted net income and EBITDA are rising; management guides for 3–5% revenue growth and mid-single-digit EBITDA growth in 2026. Valuation remains attractive relative to peers, supporting a continued 'buy' rating based on industry leadership, growth catalysts, and reasonable multiples. Read the full article on Seeking AlphaAnalyseartikel • Jun 16
Henry Schein (HSIC) Stock Could Be 7% Undervalued After BTIG Upgrade
BTIG’s recent upgrade of Henry Schein (HSIC), citing solid dental segment trends and cost-saving efforts that support profitability, has drawn fresh attention to the stock and how investors interpret evolving industry pressures. See our latest analysis for Henry Schein. The recent BTIG upgrade comes after a period where Henry Schein’s 1 month share price return of 11.51% and 1 year total shareholder return of 14.60% suggest improving momentum following more modest multi year gains. If this...Narrativ-Update • Jun 11
HSIC: Dental Demand And Cost Controls Are Expected To Support Balanced Outlook
Analysts have raised their average price target on Henry Schein to $100. They cite recent commentary around generally healthy dental markets, margin gains in Q1 driven by cost reductions, and a view that the stock has found technical support.Narrativ-Update • May 27
HSIC: Ongoing Buybacks And Dental Demand Are Expected To Drive Upside
Narrative Update on Henry Schein Henry Schein’s fair value estimate has been revised lower by about $3 to $87, as analysts fine tune assumptions on discount rates, long term growth and future P/E multiples following a mix of recent price target cuts and initiations across the Street. Analyst Commentary Recent research updates reflect a split view on Henry Schein, with several firms trimming price targets while one large bank lifted its target and a couple of houses initiated coverage with differing stances.Analyseartikel • May 08
Henry Schein, Inc. Just Recorded A 8.1% EPS Beat: Here's What Analysts Are Forecasting Next
Henry Schein, Inc. ( NASDAQ:HSIC ) shareholders are probably feeling a little disappointed, since its shares fell 5.5...Narrativ-Update • Apr 26
HSIC: Improving Dental Demand And Buybacks Are Expected To Support Upside
Narrative Update on Henry Schein The updated analyst price target for Henry Schein reflects a modest upward adjustment in fair value to about $90 per share, as analysts incorporate refreshed models following recent Q4 results, new initiations, and several target raises across the Street. Analyst Commentary Recent research updates on Henry Schein show a mixed but generally constructive tone, with several firms revising models after Q4 results and initial FY26 guidance.Narrativ-Update • Apr 11
HSIC: Rising Dental Demand And New CEO Transition Are Expected To Support Upside
Henry Schein's updated analyst price target edges slightly lower to about $89, as analysts refine their models following recent Q4 results and revised long-term growth assumptions across the Street. Analyst Commentary Street research around Henry Schein has turned more constructive overall, with several firms updating models following the Q4 print and initial FY26 guidance.Narrativ-Update • Mar 28
HSIC: Rising Dental Demand And New CEO Are Expected To Support Upside
Narrative Update on Henry Schein The updated analyst price target for Henry Schein edges up to $90.00, reflecting a series of target increases across the Street as analysts factor in better than expected Q4 results, initial FY26 guidance, refreshed models, and improved visibility on growth and end market demand. Analyst Commentary Street research on Henry Schein clusters around higher price targets following Q4 results and initial FY26 guidance, with most firms updating their models and a mix of Outperform, Overweight, Neutral, Hold, and Market Perform ratings.Narrativ-Update • Mar 13
HSIC: Improving Dental Demand And New CEO Leadership Will Support Upside
The analyst price target for Henry Schein has been raised from $83.21 to $89.79, reflecting updated models that factor in Q4 results, initial FY26 guidance, and what analysts describe as better growth visibility and a more supportive demand backdrop. Analyst Commentary Across the Street, recent research points to a more constructive stance on Henry Schein following Q4 results and initial FY26 guidance, with several firms revising their models and resetting price targets.
Neues Narrativ • Feb 25
Cloud Software And Specialty Products Will Reshape This Healthcare Distributor’s Future Earnings Power
Catalysts About Henry Schein Henry Schein is a global distributor of dental and medical products and services with growing software, specialty and value-added solutions for healthcare providers. What are the underlying business or industry changes driving this perspective?Narrativ-Update • Feb 25
HSIC: Steadier Dental Demand And CEO Transition Will Support Balanced Outlook
Analysts have nudged their fair value estimate for Henry Schein up from $78.14 to $83.21, citing higher Street price targets and commentary about steadier organic growth and improving dental demand as the main supports for the updated view. Analyst Commentary Recent Street research on Henry Schein leans constructive, with several firms lifting price targets and, in one case, upgrading the rating as sentiment around dental demand and organic growth improves.Narrativ-Update • Feb 10
HSIC: Revised Assumptions And CEO Transition Will Support Balanced Earnings Outlook
Analysts have increased their price target on Henry Schein by US$7, citing updated assumptions around revenue growth, margins, and future P/E levels that contribute to a revised valuation view. Analyst Commentary Recent research behind the US$7 upward move in the price target focuses on refreshed assumptions for Henry Schein’s revenue trajectory, margin profile, and future P/E levels.Narrativ-Update • Jan 25
HSIC: Q3 Beat And CEO Transition Will Support Range-Bound Earnings Momentum
Narrative Update: Henry Schein The analyst price target for Henry Schein has moved slightly higher by about US$0.50, as analysts point to recent price target increases and a "clean beat" in Q3 that they see as supporting a modestly higher fair value while still viewing the shares as range bound. Analyst Commentary Recent Street commentary on Henry Schein points to a mixed setup, with some bullish analysts nudging price targets higher on the back of Q3 execution and others still reluctant to see a clear path out of the stock's trading range.Narrativ-Update • Jan 11
HSIC: Q3 Beat And AI Partnerships Will Support Range-Bound Earnings Momentum
Analysts have raised their price target on Henry Schein to US$75 from US$71, citing a clean Q3 earnings beat that they view as supporting the recent share price strength, while also questioning how much further the stock can advance beyond its recent trading range. Analyst Commentary Bullish Takeaways Bullish analysts view the Q3 result as a clean beat, which they see as supporting the recent share price move and giving the higher US$75 target some fundamental backing.Narrativ-Update • Dec 19
HSIC: Q3 Beat And Buybacks Will Support Range-Bound Earnings Momentum
Analysts have modestly raised their price target on Henry Schein to approximately $75, reflecting a slightly higher fair value and future price-to-earnings multiple following a clean Q3 beat, even as they remain cautious about the stock meaningfully breaking out of its recent trading range. Analyst Commentary Street research following the Q3 report reflects a mix of cautious optimism and ongoing skepticism about Henry Schein's near term upside potential.Narrativ-Update • Dec 05
HSIC: Q3 Beat And Capital Returns Will Support Measured Earnings Momentum
Analysts modestly raised their price target on Henry Schein to $75 from $71, citing a clean Q3 beat that supports recent share gains while still questioning the stock's ability to break out above its historically defined trading range. Analyst Commentary Analysts highlight that the latest quarter delivered a clean beat versus expectations, reinforcing confidence in Henry Schein's ability to execute on its operating plan despite macro and industry headwinds.Narrativ-Update • Nov 20
HSIC: Operational Improvements and Automation Are Expected to Support Earnings Momentum
Analysts have increased their price target for Henry Schein from $75 to $77, citing expectations for moderate improvements in revenue growth and future earnings. They also pointed to optimism driven by recent operating performance and strategic initiatives.Narrativ-Update • Nov 05
HSIC: Earnings Momentum From Automation And E-Commerce Will Shape Outlook
Henry Schein’s analyst price target has increased from $73.23 to $75.15 per share, reflecting analysts’ confidence in improving margins and strategic initiatives following recent earnings results. Analyst Commentary Following the company's recent performance and updated guidance, research analysts have issued new commentary highlighting both upward momentum and remaining concerns regarding Henry Schein's outlook.Analyseartikel • Aug 08
Henry Schein, Inc. Just Missed EPS By 24%: Here's What Analysts Think Will Happen Next
NasdaqGS:HSIC 1 Year Share Price vs Fair Value Explore Henry Schein's Fair Values from the Community and select yours...Seeking Alpha • Mar 11
Henry Schein Looks Bullish (Technical Analysis)
Summary HSIC shows bullish price action, momentum, volume, and relative strength, making it an attractive investment with a 2.6 reward-to-risk ratio. The stock is in an uptrend, trading above its 30-week EMA, and has bullish short-term and long-term momentum as indicated by the PPO. Institutional buying supports bullish volume trends, and HSIC has been outperforming the S&P 500 since December 2024. Despite recent earnings not meeting expectations, future earnings and revenue growth, along with sector strength, indicate potential for price targets of $82.63 and $92.68. Read the full article on Seeking AlphaSeeking Alpha • Mar 04
Henry Schein: An Industry Leader That Offers Some Upside From Here
Summary Henry Schein is the world's largest provider of healthcare products and services for office-based dental and medical practitioners, showing consistent growth through acquisitions. Despite a 3% dip in shares, management's 2025 guidance indicates continued growth, justifying a bullish stance on the stock. The firm reported a 5.8% revenue increase in Q4 2024, driven by organic growth and acquisitions, with significant improvements in net income and operating cash flow. Henry Schein's market leadership and strategic acquisitions across various healthcare segments make it a solid investment, warranting a soft 'buy' rating. Read the full article on Seeking AlphaSeeking Alpha • Dec 10
Henry Schein: The Kind Of Business I Like But No Margin Of Safety Now
Summary Although the U.S. stock market is currently 6.9% overvalued, according to Morningstar's analysts as of December 6, 2024, there could be opportunities in undervalued sectors like healthcare. Henry Schein is a candidate surfaced by a screen in this sector. It has many characteristics that I like in companies: easy-to-understand business, and profitable, among many others. There are some short-term headwinds that investors must be aware of but not overly concerned about. No investment is so good that it is worth buying at any price, and that applies to Henry Schein, which is currently overvalued. Read the full article on Seeking AlphaSeeking Alpha • Nov 20
Henry Schein: Another Day, Another Purchase
Summary Henry Schein announced the acquisition of Acentus, a small medical product supplier, to expand its homecare medical products platform despite recent underperformance in cash flow metrics. The CGM market, where Acentus operates, is expected to grow significantly, making the acquisition strategically sound, though financial benefits remain uncertain without disclosed terms. Despite revenue growth from acquisitions, Henry Schein's profitability metrics have declined, raising concerns about its ability to meet its revised 2024 revenue and profit targets. While Henry Schein shows potential for cost savings and slight undervaluation, persistent profitability issues and investor skepticism warrant only a cautious 'buy' rating, subject to future performance. Read the full article on Seeking Alpha
Neues Narrativ • Aug 25
Critical Acquisitions And High-Growth Product Expansion Set To Transform Dental Giant
Expansion into high-growth products and strategic acquisitions aimed at increasing gross margins through improved integration and efficiency.Aktionärsrenditen
| HSIC | US Healthcare | US Markt | |
|---|---|---|---|
| 7D | 2.5% | 2.0% | 1.6% |
| 1Y | 17.7% | 28.7% | 18.6% |
Rendite im Vergleich zur Industrie: HSIC unter dem Niveau der Branche US Healthcare , die im vergangenen Jahr eine Rendite von 28.7% erzielte.
Rendite vs. Markt: HSIC entspricht dem US Markt, der im vergangenen Jahr eine Rendite von 18.6 erzielte.
Preisvolatilität
| HSIC volatility | |
|---|---|
| HSIC Average Weekly Movement | 3.4% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: HSIC hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: HSICDie wöchentliche Volatilität (3%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1932 | 25,000 | Fred Lowery | www.henryschein.com |
Henry Schein, Inc. bietet weltweit Produkte und Dienstleistungen für das Gesundheitswesen an Zahnärzte und Ärzte in eigener Praxis an. Das Unternehmen ist in den Segmenten „Global Distribution and Value-Added Services“, „Global Specialty Products“ und „Global Technology“ tätig. Der Geschäftsbereich „Global Distribution and Value-Added Services“ vertreibt Produkte zur Infektionskontrolle, Handstücke, Präventivmittel, Abformmaterialien, Komposite, Anästhetika, Zähne, Gips, Acryl, Artikulatoren, Schleifmittel, PSA-Produkte, Marken- und Generika-Arzneimittel, Impfstoffe, chirurgische Produkte, diagnostische Tests, Zahnarztstühle, Behandlungseinheiten und Leuchten, digitale Dentallabore, Röntgenzubehör und -geräte sowie Hightech- und digitale Restaurationsgeräte und bietet darüber hinaus Reparaturdienstleistungen für Geräte, Finanzdienstleistungen auf Non-Recourse-Basis, Fortbildungsangebote für Ärzte, Beratung und weitere Dienstleistungen an.
Henry Schein, Inc.'s Grundlagenzusammenfassung
| HSIC grundlegende Statistiken | |
|---|---|
| Marktanteil | US$9.85b |
| Gewinn(TTM) | US$395.00m |
| Umsatz(TTM) | US$13.38b |
24.9x
Kurs-Gewinn-Verhältnis 0.7x
Kurs-Umsatz-VerhältnisIst HSIC zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| HSIC Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$13.38b |
| Kosten der Einnahmen | US$9.21b |
| Bruttogewinn | US$4.18b |
| Sonstige Ausgaben | US$3.78b |
| Gewinn | US$395.00m |
Zuletzt gemeldete Gewinne
Mar 28, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 3.47 |
| Bruttomarge | 31.19% |
| Nettogewinnspanne | 2.95% |
| Schulden/Eigenkapital-Verhältnis | 70.6% |
Wie hat sich HSIC auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/06 09:26 |
| Aktienkurs zum Tagesende | 2026/07/02 00:00 |
| Gewinne | 2026/03/28 |
| Jährliche Einnahmen | 2025/12/27 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Henry Schein, Inc. wird von 31 Analysten beobachtet. 15 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jeffrey Johnson | Baird |
| Glen Santangelo | Barclays |
| Lawrence Marsh | Barclays |